Ocular Therapeutix (OCUL) Tops Q4 EPS by 3c

Ocular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of ($0.29), $0.03 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $13.25 million versus the consensus estimate of $16.13 million.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

You May Also Be Interested In

• Flowers Foods (FLO) Misses Q2 EPS by 3c; Offers Guidance
• Largo restructures $82.2M in debt, extending maturity to 2030
• Samsung Plans As Much As $79 Billion In Shareholder Returns - Bloomberg